AI cancer diagnostics firm Ibex Medical and Source LDPath have announced a new agreement to expand the deployment of artificial intelligence to the entire pathology network at Source.
The expansion builds on Ibex's previous work with LDPath, which was acquired earlier this year by Source to create Source LDPath, one of the largest private providers of cellular and digital pathology services in the UK. The deployment will include new AI-powered tools for diagnosing multiple tissue types and support pathologists with improved diagnostic accuracy and efficiency.
With around 275,000 women undergoing breast biopsy and 100,000 men undergoing prostate biopsy in the UK each year, NHS pathology services remain under significant pressure resulting from a shortage of pathologists, rising case numbers, and a post-pandemic backlog.
Ibex's Galen platform will be made available to the entire Source network, spanning more than 200 pathologists who will use Ibex's AI-powered workflows integrated into an in-house developed LIS and reporting system.
The Galen suite of solutions from Ibex is the first and most widely deployed AI technology in pathology, used in routine clinical practice in laboratories, hospitals, and health systems worldwide. It supports pathologists in a variety of tasks during the diagnosis of breast, prostate, and gastric biopsies and helps improve the accuracy of cancer diagnosis, reduce turnaround time, boost productivity, and improve user experience for pathologists. Galen demonstrated outstanding outcomes across multiple clinical studies performed on various tissue types and diagnostic workflows (references available).
"We are building the largest private digital pathology network in the UK, helping in mitigating the impact of the continued shortage of pathologists and addressing the NHS backlog in cancer diagnosis, which has become a national priority," added Sanj Lallie, Commercial and Digital/AI Director, Source LDPath. "We are proud to expand our diagnostic capabilities with Ibex's world-renowned AI technology, adopted at scale across our network to help ensure that cancer patients receive an accurate and timely diagnosis."
Dr Alistair Robson, FRCPath, DipRCPath and Medical Director of Source LDPath added: "I have seen first-hand how transformative and impactful AI-powered tools can be for a pathologist's work. I am encouraged by the continued rollout of Ibex AI across UK hospital trusts and am looking forward to seeing Ibex's newly announced biomarker scoring tools helping breast pathologists improve diagnosis of IHC stained slides."